Wang Denong
Tumor Glycomics Laboratory, SRI International Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA 94025-3493, USA.
Curr Trends Immunol. 2023;24:1-7.
Recognition of abnormal glycosylation in virtually any cancer type has raised a great interest in the glycan-based tumor biomarkers. Our team explored carbohydrate microarrays as a broad-spectrum immunoassay to probe the immunologically potent tumor glycan targets. This effort has led to the identification of a blood group precursor antigen SSEA-0 as a conserved breast cancer (BCA) marker. Since this immunogenic O-core glycan is normally hidden as a cryptic antigen but becomes overexpressed and surface-exposed by metastatic breast cancer cells (MBCA), its potential as a novel immunological target for precision immunotherapy against tumor metastasis warrants a focused investigation.
几乎在任何癌症类型中对异常糖基化的认识都引发了人们对基于聚糖的肿瘤生物标志物的极大兴趣。我们的团队探索了碳水化合物微阵列作为一种广谱免疫测定法，以探测具有免疫活性的肿瘤聚糖靶点。这项工作已导致鉴定出血型前体抗原SSEA-0作为一种保守的乳腺癌（BCA）标志物。由于这种具有免疫原性的O-核心聚糖通常作为一种隐蔽抗原被隐藏，但在转移性乳腺癌细胞（MBCA）中会过度表达并暴露于表面，因此其作为针对肿瘤转移的精准免疫治疗的新型免疫靶点的潜力值得重点研究。
